Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.71 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038490 | 0.89 | ADRB3 (0.66) | ADRB3ADRB2 | |
| SCHEMBL27432957 | 0.89 | ADRB3 (0.64) | ADRB3ADRB2 | |
| SCHEMBL7040736 | 0.86 | ADRB3 (0.69) | ADRB3ADRB2 | |
| SCHEMBL7610750 | 0.81 | ADRB3 (0.69) | ADRB3ADRB2 | |
| SCHEMBL7605269 | 0.81 | ADRB3 (0.69) | ADRB3ADRB2 | |
| SCHEMBL11747553 | 0.81 | ADRB3 (0.74) | ADRB3ADRB2 | |
| Hydrochloric Acid SCHEMBL11744017 | 0.80 | ADRB3 (0.72) | ADRB3ADRB2 | |
| SCHEMBL3136753 | 0.80 | ADRB3 (0.72) | ADRB3ADRB2 | |
| SCHEMBL7610796 | 0.80 | ADRB3 (0.67) | ADRB3ADRB2 | |
| SCHEMBL5143889 | 0.79 | ADRB3 (0.69) | ADRB3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0659737-B1 | Catecholamine surrogates useful as beta 3 agonists | BRISTOL MYERS SQUIBB CO (US) | 2003-03-26 | — | — | EP | claimed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | claimed |
| EP-0659737-B1 | Catecholamine surrogates useful as beta 3 agonists | BRISTOL MYERS SQUIBB CO (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |